DDInter702 DDInter1658
A semisynthetic derivative of podophyllotoxin that exhibits antitumor activity. Etoposide inhibits DNA synthesis by forming a complex with topoisomerase II and DNA. This complex induces breaks in double stranded DNA and prevents repair by topoisomerase II binding. Accumulated breaks in DNA prevent entry into the mitotic phase of cell division, and lead to cell death. Etoposide acts primarily in the G2 and S phases of the cell cycle.
Selpercatinib is a kinase inhibitor with enhanced specificity for RET tyrosine kinase receptors (RTKs) over other RTK classes.[A202055, A202052, L13604] Enhanced RET (Rearranged during transfection) oncogene expression is a hallmark of many cancers. Although multikinase inhibitors, including [cabozantinib], [ponatinib], [sorafenib], [sunitinib], and [vandetanib], have shown efficacy in RET-driven cancers, their lack of specificity is generally associated with substantial toxicity. Selpercatinib (LOXO-292) and pralsetinib (BLU-667) represent the first generation of specific RET RTK inhibitors for the treatment of RET-driven cancers.[A202049, A202055, A202052, L13604] Although selpercatinib is currently still under investigation in clinical trial NCT04211337, it was granted accelerated FDA approval on May 8, 2020, for specific RET-driven cancer indications. It is currently marketed under the brand name RETEVMO™ by Loxo Oncology Inc. Selpercatinib is also approved by the European Commission.
Etoposide {u} (Compound) resembles {v} (Compound) Podofilox
Etoposide {u} (Compound) treats {v} (Disease) urinary bladder cancer
Etoposide {u} (Compound) binds {v} (Gene) GSTT1
Etoposide {u} (Compound) upregulates {v} (Gene) COL11A1
Etoposide {u} (Compound) is included by {v} (Pharmacologic Class) Topoisomerase Inhibitors
Etoposide {u} (Compound) downregulates {v} (Gene) AURKB
Etoposide {u} (Compound) causes {v} (Side Effect) Necrolysis epidermal
Etoposide {u} may cause a minor interaction that can limit clinical effects when taken with {v} Sparfloxacin
Etoposide {u} may cause a minor interaction that can limit clinical effects when taken with {v} Trovafloxacin
Etoposide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Alefacept
Etoposide (Compound) resembles Podofilox (Compound)
Etoposide (Compound) treats urinary bladder cancer (Disease)
Etoposide (Compound) binds GSTT1 (Gene)
Etoposide (Compound) upregulates COL11A1 (Gene)
Etoposide (Compound) is included by Topoisomerase Inhibitors (Pharmacologic Class)
Etoposide (Compound) downregulates AURKB (Gene)
Etoposide (Compound) causes Necrolysis epidermal (Side Effect)
Etoposide may cause a minor interaction that can limit clinical effects when taken with Sparfloxacin
Etoposide may cause a minor interaction that can limit clinical effects when taken with Trovafloxacin
Etoposide may cause a moderate interaction that could exacerbate diseases when taken with Alefacept